- Full Year 2024 Eisai Co Ltd Earnings Presentation TranscriptMay 15, 2024
- Eisai Co Ltd Information Meeting TranscriptMar 08, 2024
- Q3 2024 Eisai Co Ltd Earnings Presentation TranscriptFeb 06, 2024
- Eisai Co Ltd Launch of LEQEMBI in Japan TranscriptDec 13, 2023
- Q2 2024 Eisai Co Ltd Earnings Presentation TranscriptNov 07, 2023
- Q1 2024 Eisai Co Ltd Earnings Presentation TranscriptAug 02, 2023
- Eisai Co Ltd Media and Investor Conference TranscriptJul 07, 2023
- Full Year 2023 Eisai Co Ltd Earnings Presentation TranscriptMay 15, 2023
- Eisai Co Ltd Information Meeting TranscriptMar 10, 2023
- Q3 2023 Eisai Co Ltd Earnings Call TranscriptFeb 06, 2023Earnings
- Eisai Co Ltd Approach to US Pricing for LEQEMBI Briefing TranscriptJan 07, 2023
- Eisai Co Ltd Clarity AD Study Briefing TranscriptNov 30, 2022
- Q2 2023 Eisai Co Ltd Earnings Call TranscriptNov 07, 2022Earnings
- Eisai Co Ltd Lecanemab Phase 3 Study Met Primary Endpoint Call TranscriptSep 28, 2022
- Q1 2023 Eisai Co Ltd Earnings Call TranscriptAug 05, 2022Earnings
- Full Year 2022 Eisai Co Ltd Earnings Presentation TranscriptMay 13, 2022
- Eisai Co Ltd Information Meeting TranscriptMar 16, 2022
- Q3 2022 Eisai Co Ltd Earnings Call TranscriptFeb 03, 2022Earnings
- Q2 2022 Eisai Co Ltd Earnings Call TranscriptNov 01, 2021Earnings
- Q1 2022 Eisai Co Ltd Earnings Call TranscriptAug 04, 2021Earnings
- Eisai Co Ltd FDA Grants Accelerated Approval for ADUHELM Presentation TranscriptJun 09, 2021
- Full Year 2021 Eisai Co Ltd Earnings Call TranscriptMay 12, 2021Earnings
- Eisai Co Ltd Information Meeting TranscriptMar 26, 2021
- Q3 2021 Eisai Co Ltd Earnings Call TranscriptFeb 03, 2021Earnings
- Q2 2021 Eisai Co Ltd Earnings Call TranscriptNov 05, 2020Earnings
- Q1 2021 Eisai Co Ltd Earnings Call TranscriptAug 03, 2020Earnings
- Full Year 2020 Eisai Co Ltd Earnings Call TranscriptMay 13, 2020Earnings
- Eisai Co Ltd Information Meeting TranscriptMar 06, 2020
- Q3 2020 Eisai Co Ltd Earnings Presentation and Conference Call TranscriptJan 31, 2020
- Full Year 2019 Eisai Co Ltd Earnings Presentation and Conference Call TranscriptMay 13, 2019
- Eisai Co Ltd Information Meeting TranscriptMar 08, 2019
Eisai Co Ltd Launch of LEQEMBI in Japan Transcript
Thank you very much for taking your time to attend the conference today. It is now time. We would now like to begin media investor conference for the launch of LEQEMBI in Japan. This is a hybrid presentation, both in person here as well as with attendance online. Those of you who are attending in person, please find the press release. Those of you who are participating online, you are able to download the press release from the chat box. There are English and Japanese versions available.
I would now like to introduce the presenter Mr. Haruo Naito, Representative Corporate Officer and CEO. Mr. Naito, CEO, please.
Thank you. At Chuikyou, Central Social Insurance Medical Council, drug price and Optimal Clinical Use Guidelines were approved. On this occasion, regarding the launch of LEQEMBI, we would like to share with you our thinking. Please refer to the material distributed to you as I will be discussing in line with that material. At its
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)